Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 6:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 930 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cap Clear all
Completed Not applicable Interventional

Ashwagandha for Nighttime Waking

NCT07151261
View directory record Official record
Conditions
Disturbed Sleep
Interventions
Ashwagandha, Placebo
Dietary Supplement · Other
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 18, 2026, 6:50 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The Utility of Cap Colonoscopy in Increasing Adenoma Detection Rate

NCT01601431
View directory record Official record
Conditions
Adenoma
Interventions
Cap Assisted Colonoscopy, Conventional colonoscopy
Device
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 80 Years
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Oct 18, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers

NCT02792829
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lenvatinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 18, 2026, 6:50 PM EDT
Recruiting Phase 2Phase 3 Interventional

Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

NCT06841679
View directory record Official record
Conditions
Gastric or Gastroesophageal Junction Adenocarcinoma
Interventions
Utidelone Capsule, Fluoropyrimidine- and Platinum-containing Therapy, Oxaliplatin, PD-1 inhibitor, Capecitabine
Drug
Lead sponsor
Beijing Biostar Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 18, 2026, 6:50 PM EDT
Completed Phase 3 Interventional Results available

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients

NCT02008942
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PL2200 Aspirin Capsules, Enteric-coated aspirin caplets
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
21 Years to 79 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
3
States / cities
Miami, Florida • Lenexa, Kansas • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 18, 2026, 6:50 PM EDT
Recruiting Not applicable Interventional

XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)

NCT06895070
View directory record Official record
Conditions
Heart Transplant, Heart Failure, Transplant; Failure, Heart
Interventions
Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Assist Transport (XHAT)
Device
Lead sponsor
XVIVO Perfusion
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 18, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules

NCT03509883
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Drug: Apixaban sprinkle capsules, Experimental: Apixaban tablets followed by apixaban sprinkle capsules
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2020 · Synced Oct 18, 2026, 6:50 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Evaluation of PillCam® Colon 2 Capsule Endoscopy Regimen

NCT01185002
View directory record Official record
Conditions
Colonoscopy, Endoscopy
Interventions
PillCam® COLON 2 procedure using MgC boosts, PillCam® COLON 2 procedure using Suprep boosts, PillCam® COLON 2 procedure using reduced dose of Suprep boosts
Other
Lead sponsor
Medtronic - MITG
Industry
Eligibility
50 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
7
States / cities
Huntsville, Alabama • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 18, 2026, 6:50 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

The Biologic Onset of Crohn's Disease: A Screening Study in First Degree Relatives

NCT03291743
View directory record Official record
Conditions
Crohn Disease, Genetic Predisposition, IBD
Interventions
Capsule endoscopy
Device
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 18, 2026, 6:50 PM EDT
Completed Phase 4 Interventional Results available

Oracea Soolantra Association in Participants With Severe Rosacea

NCT03075891
View directory record Official record
Conditions
Rosacea
Interventions
Ivermectin 1% cream, Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules, Oral placebo capsules
Drug · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Fort Smith, Arkansas • Sacramento, California • Boca Raton, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 18, 2026, 6:50 PM EDT
Completed Phase 3 Interventional

A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease

NCT00002397
View directory record Official record
Conditions
HIV Infections, AIDS-Associated Nephropathy
Interventions
Nelfinavir mesylate, Saquinavir, Lamivudine, Stavudine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 6:50 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

High-Resolution Measurements of Diet-Microbiome Interactions

NCT07856823
View directory record Official record
Conditions
IBS (Irritable Bowel Syndrome)
Interventions
Inulin, Low-fiber control breakfast shake, Atmo Gas-Sensing Capsule, CapScan Regional Fluid-Sampling Capsule
Dietary Supplement · Other · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 18, 2026, 6:50 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers

NCT03852446
View directory record Official record
Conditions
Healthy
Interventions
Indoximod HCL (F2) tablets, Indoximod base formulation, Placebo
Drug · Other
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 18, 2026, 6:50 PM EDT
Completed Phase 3 Interventional Results available

Study of Meloxicam Capsules in Subjects With Osteoarthritis of the Knee or Hip

NCT01801735
View directory record Official record
Conditions
Osteoarthritis
Interventions
Meloxicam Test Capsules
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
40 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Carmichael, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 18, 2026, 6:50 PM EDT
Completed Phase 3 Interventional

Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.

NCT00047580
View directory record Official record
Conditions
Multiple Sclerosis, Muscle Spasticity, Spinal Cord Injury, Stroke
Interventions
tizanidine hydrochloride capsule
Drug
Lead sponsor
Elan Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
16
States / cities
Tucson, Arizona • Encinitas, California • Northridge, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 18, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions

NCT01161966
View directory record Official record
Conditions
Healthy
Interventions
Zonisamide, Zonegran
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2010 · Synced Oct 18, 2026, 6:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Stork OTC: Collection, Placement & Delivery

NCT02038322
View directory record Official record
Conditions
Safety and Usability
Interventions
The Stork - Conception Aid
Device
Lead sponsor
Rinovum Women's Health, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Oct 18, 2026, 6:50 PM EDT
Completed Phase 3 Interventional Results available

Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension

NCT00281580
View directory record Official record
Conditions
Hypertension
Interventions
Amlodipine 5 mg, Placebo, Telmisartan 20 mg, Telmisartan 40 mg, Amlodipine 10 mg, Telmisartan 80 mg, Amlodipine 2.5 mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
101
States / cities
Fairhope, Alabama • Huntsville, Alabama • Chandler, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 18, 2026, 6:50 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Two Forms of Saquinavir Combined With Other Anti-HIV Drugs in HIV-Infected Infants and Children

NCT00002380
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
6 Months to 13 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 6:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Bioequivalence Study of Oseltamivir Phosphate and TAMIFLU Under Fed Condition in Healthy Volunteers

NCT04536415
View directory record Official record
Conditions
Bioequivalence
Interventions
Oseltamivir Phosphate 75 mg capsules, Tamiflu capsules 75 mg
Drug
Lead sponsor
Austarpharma, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 18, 2026, 6:50 PM EDT
Completed Phase 3 Interventional Results available

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)

NCT00690820
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Exocrine Insufficiency
Interventions
Pancrelipase Delayed Release, Placebo Comparator
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
7 Years to 11 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
10
States / cities
Iowa City, Iowa • Louisville, Kentucky • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2010 · Synced Oct 18, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cefdinir Capsules 300 mg, Fasting

NCT00835484
View directory record Official record
Conditions
Healthy
Interventions
Cefdinir Capsules 300 mg, OMNICEF® 300 mg
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 18, 2026, 6:50 PM EDT
Terminated Phase 2 Interventional Results available

Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer

NCT01928485
View directory record Official record
Conditions
Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
active surveillance, Sunphenon, laboratory biomarker analysis, Questionnaire Administration
Other · Drug
Lead sponsor
Sanjay Gupta PhD
Other
Eligibility
45 Years to 85 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 18, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immunogenicity of ND1.1 by Delivery Directly to the Ileum

NCT01698060
View directory record Official record
Conditions
Avian Influenza
Interventions
ND1.1
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Oct 18, 2026, 6:50 PM EDT